---
title: "Traws Pharma, Inc. 1Q 2026: Revenue $0 EPS $(0.53) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286555967.md"
description: "Traws Pharma, Inc. reported Q1 2026 results with $0 revenue and a net loss of $5.69M, or EPS of $(0.53). Cash on hand is $3.1M, raising concerns about its ability to continue without further financing. The company is advancing Phase 2 trials for its drugs and has ongoing FDA interactions. An equity financing of up to $60M was executed in April 2026 to support operations and clinical programs."
datetime: "2026-05-15T11:21:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286555967.md)
  - [en](https://longbridge.com/en/news/286555967.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286555967.md)
---

# Traws Pharma, Inc. 1Q 2026: Revenue $0 EPS $(0.53) — 10-Q Summary

Traws Pharma, Inc. reported results for the first quarter of 2026, posting no revenue and a net loss attributable to common stockholders of $5.69M, or diluted EPS of $(0.53), while cash on hand was $3.1M and the company said there is substantial doubt about its ability to continue without additional financing.

**Financial Highlights**

-   Revenue was $0 for Q1 2026, down from $57K in Q1 2025.
-   Net loss attributable to common stockholders was $5.69M for Q1 2026, versus net income of $15.08M in Q1 2025.
-   Diluted earnings per share was $(0.53) for Q1 2026, compared with diluted EPS of $2.09 in Q1 2025.

**Business Highlights**

-   Cash & going concern: Cash was $3.1M as of March 31, 2026, and the company disclosed substantial doubt about its ability to continue as a going concern without additional financing.
-   Clinical progress: Advanced Phase 2 trials for ratutrelvir and tivoxavir marboxil; Phase 2 enrollment for ratutrelvir was completed.
-   Regulatory: Ongoing FDA interactions for tivoxavir (pre-IND Type B and Type D meetings); the U.S. IND for tivoxavir remains on clinical hold pending resolution of toxicology matters.
-   Financing: In April 2026 the company executed an equity financing (pro forma structure up to $60M) to fund operations and clinical programs.
-   Pipeline and strategy: The portfolio includes four clinical programs across influenza, COVID-19 antivirals and oncology; oncology development is paused while pursuing business development or partnership options.

Original SEC Filing: Traws Pharma, Inc. \[ TRAW \] - 10-Q - May. 15, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [TRAW.US](https://longbridge.com/en/quote/TRAW.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

- [NeOnc Advances Glioma Programs and Strengthens Financial Position](https://longbridge.com/en/news/286826865.md)
- [Bristol-Myers Squibb-Anthropic AI Deal Targets Faster Drug Discovery](https://longbridge.com/en/news/287100303.md)
- [<![CDATA[Pharmaceutical Executive Daily: FDA Approves Baxdrostat]]>](https://longbridge.com/en/news/286807703.md)
- [Relay drug shows early promise against rare blood vessel diseases](https://longbridge.com/en/news/287094432.md)
- [Eton Pharmaceuticals Adds Another 2026 Launch As It Secures U.S. Rights To IMPAVIDO](https://longbridge.com/en/news/287025596.md)